Oslo, 11 November 2024) Medistim ASA (OSE: MEDI) is a niche market leader within
ultrasound technology with headquarters in Oslo, Norway. Medistim develops and
commercializes medical equipment for use within cardiac, vascular and transplant
surgery. 

The company is pleased to announce the successful completion of its Early Access
program for the new MiraQTM INTUI software platform. The official product launch
is set for December 13 at the International Coronary Congress (ICC) in London.

Medistim's devices for Transit Time Flow Measurement (TTFM) and High-Frequency
Ultrasound (HFUS) are currently utilized in approximately 37% of the 700,000
coronary artery bypass graft (CABG) procedures performed worldwide each year.
While TTFM is already the standard of care in many European and Asian countries,
significant growth opportunities remain in key markets such as the United
States. Driving global adoption and establishing routine use will depend on
continued product innovation, focusing on enhanced user-friendliness and
delivering greater clinical value.

Built on a cutting-edge, future-proof software architecture, INTUI sets a new
standard for Medistim's MiraQTM technology. Its redesigned user interface is
engineered to enhance procedural efficiency in surgery, offering simplified
navigation, quicker access to critical data, and improved data
interpretation-ultimately streamlining workflow and optimizing performance.

"Developed and tested in collaboration with an international team of cardiac
surgeons, we are confident that INTUI offers advanced support for clinical
decision-making, with the potential to improve patient safety and outcomes,"
said Kari E. Krogstad, President and CEO of Medistim. "Our mission is to equip
surgical teams with tools that simplify complex procedures, delivering
exceptional ease of use. And this is just the beginning-we are excited to expand
this technology to vascular applications in the near future."

About Medistim:
Medistim was established in 1984 and has a track record of profitable growth
over the past 20 years.  The company is a pioneer within its segment and
continues to invest in new product development.  Medistim has wholly owned
subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark,
and Norway, in addition to the about 60 distributors in Europe, Asia, Middle
East, Africa, Canada and South America.   For more information, visit the
Medistim home page:  www.medistim.com 

For more information, contact: 

President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110  
Email: kari.krogstad@medistim.com 

CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940  
Email: thomas.jakobsen@medistim.com